Aljaberi, N; Tronconi, E; Schulert, G; Grom, AA; Lovell, DJ; Huggins, JL; Henrickson, M; Brunner, HI.
The use of S100 proteins testing in juvenile idiopathic arthritis and autoinflammatory diseases in a pediatric clinical setting: a retrospective analysis.
Pediatric Rheumatology.
2020;
18.
Cron, RQ; Schulert, GS; Tattersall, RS.
Defining the scourge of COVID-19 hyperinflammatory syndrome.
The Lancet. Rheumatology.
2020;
2:e727-e729.
Lin, B; Berard, R; Al Rasheed, A; Aladba, B; Kranzusch, PJ; Henderlight, M; Grom, A; Kahle, D; Torreggiani, S; Aue, AG; et al.
A novel STING1 variant causes a recessive form of STING-associated vasculopathy with onset in infancy (SAVI).
Journal of Allergy and Clinical Immunology.
2020;
146:1204-1208.e6.
Henderson, LA; Canna, SW; Friedman, KG; Gorelik, M; Lapidus, SK; Bassiri, H; Behrens, EM; Ferris, A; Kernan, KF; Schulert, GS; et al.
American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 1.
Arthritis and Rheumatology.
2020;
72:1791-1805.
Schulert, GS.
The Storm Beneath the Storm: MAS-HLH in Inflammatory Myopathies.
Journal of Rheumatology.
2020;
47:1461-1463.
Schulert, GS.
Can tocilizumab calm the cytokine storm of COVID-19?.
The Lancet. Rheumatology.
2020;
2:e449-e451.
Canna, SW; Schulert, GS; de Jesus, A; Pickering, A; Brunner, H; Gadina, M; Levine, S; Goldbach-Mansky, R; Boutelle, J; Sinha, R; et al.
Proceedings from the 2nd Next Gen Therapies for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome symposium held on October 3-4, 2019.
Pediatric Rheumatology.
2020;
18.
Henderson, LA; Canna, SW; Schulert, GS; Volpi, S; Lee, PY; Kernan, KF; Caricchio, R; Mahmud, S; Hazen, MM; Halyabar, O; et al.
On the Alert for Cytokine Storm: Immunopathology in COVID-19.
Arthritis and Rheumatology.
2020;
72:1059-1063.
Schulert, GS; Cron, RQ.
The genetics of macrophage activation syndrome.
Genes and Immunity.
2020;
21:169-181.
de Jesus, AA; Hou, Y; Brooks, S; Malle, L; Biancotto, A; Huang, Y; Calvo, KR; Marrero, B; Moir, S; Oler, AJ; et al.
Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases.
Journal of Clinical Investigation.
2020;
130:1669-1682.
Verweyen, E; Holzinger, D; Weinhage, T; Hinze, C; Wittkowski, H; Pickkers, P; Albeituni, S; Verbist, K; Nichols, KE; Schulert, G; et al.
Synergistic Signaling of TLR and IFNα/β Facilitates Escape of IL-18 Expression from Endotoxin Tolerance.
American Journal of Respiratory and Critical Care Medicine.
2020;
201:526-539.
Ferrara, G; Giani, T; Lieberman, SM; Kremer, C; Hong, S; Indolfi, G; Schulert, G; Cron, RQ; Mannion, ML; Lapidus, S; et al.
Alagille Syndrome and Chronic Arthritis: An International Case Series.
Journal of Pediatrics.
2020;
218:228-230.e1.
Yasin, S; Fall, N; Brown, RA; Henderlight, M; Canna, SW; Girard-Guyonvarc'h, C; Gabay, C; Grom, AA; Schulert, GS.
IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome.
Rheumatology.
2020;
59:361-366.
Yasin, S; Solomon, K; Canna, SW; Girard-Guyonvarc'h, C; Gabay, C; Schiffrin, E; Sleight, A; Grom, AA; Schulert, GS.
IL-18 as therapeutic target in a patient with resistant systemic juvenile idiopathic arthritis and recurrent macrophage activation syndrome.
Rheumatology.
2020;
59:442-445.
Lee, PY; Schulert, GS; Canna, SW; Huang, Y; Sundel, J; Li, Y; Hoyt, KJ; Blaustein, RB; Wactor, A; Do, T; et al.
Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis.
Annals of the Rheumatic Diseases.
2020;
79:225-231.
Abid, Q; Best Rocha, A; Larsen, CP; Schulert, G; Marsh, R; Yasin, S; Patty-Resk, C; Valentini, RP; Adams, M; Baracco, R.
APOL1-Associated Collapsing Focal Segmental Glomerulosclerosis in a Patient With Stimulator of Interferon Genes (STING)-Associated Vasculopathy With Onset in Infancy (SAVI).
American Journal of Kidney Diseases.
2020;
75:287-290.